Comparative analysis of dalbavancin versus other antimicrobial options for gram-positive cocci infections: effectiveness, hospital stay and mortality
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Horcajada Gallego, Juan Pablo
- dc.contributor.author de Pablo-Miró, Mar
- dc.contributor.author Pujol-Ruiz¸ Sergi
- dc.contributor.author Iftimie, Simona Mihaela
- dc.contributor.author Arenas-Miras, María Del Mar
- dc.contributor.author López Montesinos, Inmaculada
- dc.contributor.author Duran Jordà, Xavier, 1974-
- dc.contributor.author Anglès, Albert
- dc.contributor.author Grau Cerrato, Santiago
- dc.contributor.author Horcajada Gallego, Juan Pablo
- dc.date.accessioned 2022-07-18T06:41:44Z
- dc.date.available 2022-07-18T06:41:44Z
- dc.date.issued 2021
- dc.description.abstract Dalbavancin is a new antibiotic that is effective against Gram-positive microorganisms, including methicillin-resistant Staphylococci, and offers the possibility of administering intravenous therapy once weekly in an ambulatory setting. We conducted a multicenter observational case-control study, comparing all patients who received dalbavancin (cases) with hospitalized patients who were treated instead with daptomycin, linezolid or vancomycin (controls), based on clinical diagnosis, main microorganism involved, and age. The primary outcome was the length of hospital stay after starting the study antimicrobial. Secondary outcomes were 7-day and 30-day efficacy, 30-day mortality, 90-day recurrence, 90-day and 6-month hospitalization, presence of adverse events and healthcare-associated infections; 161 patients (44 cases and 117 controls) were included. Bivariate analysis showed that dalbavancin reduced the total length of hospital stay (p < 0.001), with fewer 90-day recurrences (p = 0.005), 6-month hospitalizations related to the same infection (p = 0.004) and non-related hospitalizations (p = 0.035). Multivariate analyses showed that length of hospital stay was significantly shorter in patients treated with dalbavancin (-12.05 days 95% CI [-17.00, -7.11], p < 0.001), and 30-day efficacy was higher in the dalbavancin group (OR 2.62 95% CI [1.07, 6.37], p = 0.034). Although sample size of the study may be a limitation, we can conclude that Dalbavancin is a useful antimicrobial drug against Gram-positive infections, including multidrug-resistant pathogens, and allows for a remarkable reduction in length of hospital stay with greater 30-day efficacy.
- dc.format.mimetype application/pdf
- dc.identifier.citation de Pablo-Miró M, Pujol-Ruiz S, Iftimie S, Arenas-Miras MDM, López-Montesinos I, Duran-Jordà X, et al. Comparative analysis of dalbavancin versus other antimicrobial options for gram-positive cocci infections: effectiveness, hospital stay and mortality. Antibiotics (Basel). 2021 Oct 24; 10(11): 1296. DOI: 10.3390/antibiotics10111296
- dc.identifier.doi http://dx.doi.org/10.3390/antibiotics10111296
- dc.identifier.issn 2079-6382
- dc.identifier.uri http://hdl.handle.net/10230/53753
- dc.language.iso eng
- dc.publisher MDPI
- dc.rights Copyright © 2021 by Mar de Pablo-Miró. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Dalbavancin
- dc.subject.keyword Effectiveness
- dc.subject.keyword Gram-positive
- dc.subject.keyword Hospital stay
- dc.subject.keyword Methicillin-resistant staphylococci
- dc.subject.keyword Mortality
- dc.subject.keyword Multidrug-resistant gram-positive cocci
- dc.title Comparative analysis of dalbavancin versus other antimicrobial options for gram-positive cocci infections: effectiveness, hospital stay and mortality
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion